Brigatinib (Alunbrig) for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer - Details


( Last Updated : May 6, 2021)
Generic Name:
Brigatinib
Project Status:
Active
Therapeutic Area:
(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
Takeda Canada Inc.
Brand Name:
Alunbrig
Project Line:
Reimbursement Review
Project Number:
PC0230-000
NOC Date:

Details


Tumour Type:
Lung
Indications:
Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Funding Request:
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.
Review Status:
Notification to Implement Issued
Pre Noc Submission:
On
Sponsor:
Takeda Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Funding Request:
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.
pERC Meeting:
Final Recommendation Issued: